GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: PRO 140 | PRO-140 | PRO140 | Vyrologix®
Compound class:
Antibody
Comment: Leronlimab (PRO140) is a humanized anti-CCR5 (C-C motif chemokine receptor 5) monoclonal antibody [5-6]. It was originally developed by CytoDyn as a novel strategy to manage CCR5-tropic HIV infection [4].
SARS-CoV-2 and COVID-19: Leronlimab has been administered to a number of patients with severe COVID-19, to determine its potential to reduce cytokine storm caused by this disease. |
Classification ![]() |
|
| Compound class | Antibody |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 10751 | leronlimab |
Synonyms ![]() |
| PRO 140 | PRO-140 | PRO140 | Vyrologix® |
Database Links ![]() |
|
| Specialist databases | |
| GPCRdb Ligand | leronlimab |
| IMGT/mAb-DB | 807 |
| Other databases | |
| GtoPdb PubChem SID | 405560193 |
| Search PubMed clinical trials | leronlimab |
| Search PubMed titles | leronlimab |
| Search PubMed titles/abstracts | leronlimab |